Contact this trialFirst, we need to learn more about you.
Immunotherapy
Pembrolizumab Combination Therapy for Non-Small Cell Lung Cancer
Recruiting1 awardPhase 2
New York, New York
This trial is looking at the efficacy and safety of two different drugs in combination with pembrolizumab for people with NSCLC who have been treated with anti-PD-L1 therapy before.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service